ARA-290
Performance & EnduranceTissue-protective peptide derived from EPO without erythropoietic effects, for neuropathy and inflammation.
Key Benefits
- ✓Tissue protection without EPO effects
- ✓Reduces neuropathic pain
- ✓Anti-inflammatory
- ✓No blood thickening
- ✓Treats diabetic neuropathy
- ✓May help autoimmune conditions
Dosing Information
Detailed Protocol
Administered via subcutaneous injection. In clinical trials, typically dosed several times per week. Under investigation, not yet approved.
About ARA-290
ARA-290 (cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor without stimulating red blood cell production. It has tissue-protective and anti-inflammatory effects. Studied for diabetic neuropathy and sarcoidosis.
Research Notes
Phase 2 trials show benefits for diabetic peripheral neuropathy and sarcoidosis. Separates EPO tissue-protective effects from red blood cell effects.
Potential Side Effects
- •Generally well tolerated
- •Minimal side effects in studies
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.